Investor’s Business Daily |
Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe
Investor’s Business Daily Sanofi (SNY) and Regeneron Pharmaceuticals' (REGN) Dupixent is off to a strong start in the U.S., but revenue from the eczema drug lagged in Europe, an analyst said Wednesday after Sanofi's fourth-quarter report. X Dupixent generated 118 million euros … |
